AVALO THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2017 was 0.00 shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 0.00 shares.
- AVALO THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2017-12-31 | 0.00 shares 10-K · filed 2018-04-02 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-04-02 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |